CPA
BHVN icon

Capital Performance Advisors’s Biohaven BHVN Stock Holding History

Capital Performance Advisors’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-22
Closed -$1.1K – 479
2024
Q3 		$1.1K Buy
+22
New +$856 ﹤0.01% 1861

Other funds holding BHVN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Performance Advisors's BHVN Position: Q4 2024 in Review

Capital Performance Advisors sold out of Biohaven (BHVN) in Q4 2024, closing a stake of 22 shares — an estimated $1.1K sold.

Capital Performance Advisors first reported a position in BHVN in Q3 2024 and held it in 1 quarter. The position peaked at $1.1K in Q3 2024. 256 funds tracked by Wall St. Rank hold BHVN as of Q4 2024.

  • Capital Performance Advisors reported no remaining Biohaven position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 22 Biohaven shares in Q4 2024, an estimated $1.1K.
  • Capital Performance Advisors first reported a position in Biohaven in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Biohaven position peaked at $1.1K in Q3 2024.
  • 256 funds tracked by Wall St. Rank held Biohaven as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.